ROG:XV: PDL1 Tecentriq predictably worse on overall survival than PD1s again

Predictable failure of ROG anti PDL1 Tecentriq in Bladder cancer where anti PD1 succeeded:

As we feared, Roche today announced that its anti PD-L1 Tecentriq failed to show overall survival benefit in its confirmatory 2nd line bladder cancer phase III (IMvigor211). Last year, the FDA granted provisional accelerated approval, pending this confirmatory phase III trial that has now failed...